Distinguished in Metastatic Brain Tumor

Dr. Roger Packer

Neurology | Pediatrics
111 Michigan Ave Nw, 
Washington, DC 
Distinguished in Metastatic Brain Tumor
111 Michigan Ave Nw, 
Washington, DC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Roger Packer is a Neurologist and a Pediatrics provider in Washington, Washington, D.c.. Dr. Packer is rated as a Distinguished provider by MediFind in the treatment of Metastatic Brain Tumor. His top areas of expertise are Brain Tumor, Diffuse Midline Glioma H3 K27M-Mutant, Medulloblastoma, and Gliomatosis Cerebri.

His clinical research consists of co-authoring 255 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles in the study of Metastatic Brain Tumor.

Specialties
Neurology
Pediatrics
Licenses
Psychiatry & Neurology in DC
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

111 Michigan Ave Nw, Washington, DC 20010

Additional Areas of Focus

Dr. Packer has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects With Recurrent/Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma
Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects With Recurrent/Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma
Enrollment Status: Active_not_recruiting
Publish Date: September 29, 2025
Intervention Type: Biological
Study Drug: APX005M
Study Phase: Phase 1
Open-label, Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
Open-label, Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
Enrollment Status: Completed
Publish Date: August 27, 2025
Intervention Type: Drug
Study Drug: Crizotinib
Study Phase: Phase 2
Pediatric Neuro-Oncology Consortium (PNOC)-002: Safety, Phase 0, and Pilot Efficacy Study of Vemurafenib, an Oral Inhibitor of BRAFV600E, in Children and Young Adults With Recurrent/Refractory BRAFV600E- or BRAF Ins T Mutant Brain Tumors
Pediatric Neuro-Oncology Consortium (PNOC)-002: Safety, Phase 0, and Pilot Efficacy Study of Vemurafenib, an Oral Inhibitor of BRAFV600E, in Children and Young Adults With Recurrent/Refractory BRAFV600E- or BRAF Ins T Mutant Brain Tumors
Enrollment Status: Completed
Publish Date: August 03, 2025
Intervention Type: Drug
Study Drug: Vemurafenib
Study Phase: Early Phase 1
A Phase 1/2 Trial of the MEK Inhibitor Selumetinib and Bromodomain Inhibitor With Durvalumab (MEDI4736), a PD-L1 Antibody for Sarcomas Including Malignant Peripheral Nerve Sheath Tumors (NF112)
A Phase 1/2 Trial of the MEK Inhibitor Selumetinib and Bromodomain Inhibitor With Durvalumab (MEDI4736), a PD-L1 Antibody for Sarcomas Including Malignant Peripheral Nerve Sheath Tumors (NF112)
Enrollment Status: Not_yet_recruiting
Publish Date: June 08, 2025
Intervention Type: Drug
Study Drug: Selumetinib
Study Phase: Phase 2
A Phase II Study of Binimetinib in Children and Adults With NF1 Associated Plexiform Neurofibromas (PNOC010)
A Phase II Study of Binimetinib in Children and Adults With NF1 Associated Plexiform Neurofibromas (PNOC010)
Enrollment Status: Completed
Publish Date: May 02, 2025
Intervention Type: Drug
Study Drug: Binimetinib
Study Phase: Phase 2
A Phase II Trial of Poly-ICLC for Progressive, Previously Treated Low-Grade Gliomas in Children and Young Adults With Neurofibromatosis Type 1
A Phase II Trial of Poly-ICLC for Progressive, Previously Treated Low-Grade Gliomas in Children and Young Adults With Neurofibromatosis Type 1
Enrollment Status: Terminated
Publish Date: March 21, 2025
Intervention Type: Drug
Study Drug: Poly ICLC
Study Phase: Phase 2
A Phase 2 Dose-escalation Study Examining the Safety, Pharmacokinetics, and Preliminary Efficacy of Ascending Drug and Energy Dose Combinations for Sonodynamic Therapy Using SONALA-001 in Combination with Exablate 4000 Type 2.0 MR-Guided Focused Ultrasound in Subjects with Diffuse Intrinsic Pontine Glioma (DIPG) and Diffuse Midline Glioma (DMG)
A Phase 2 Dose-escalation Study Examining the Safety, Pharmacokinetics, and Preliminary Efficacy of Ascending Drug and Energy Dose Combinations for Sonodynamic Therapy Using SONALA-001 in Combination with Exablate 4000 Type 2.0 MR-Guided Focused Ultrasound in Subjects with Diffuse Intrinsic Pontine Glioma (DIPG) and Diffuse Midline Glioma (DMG)
Enrollment Status: Suspended
Publish Date: September 19, 2024
Intervention Type: Combination product
Study Drug: SONALA-001+MR-Guided Focused Ultrasound device
Study Phase: Phase 2
Phase 1 Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma
Phase 1 Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma
Enrollment Status: Completed
Publish Date: April 25, 2024
Intervention Type: Drug
Study Drug: LBH589
Study Phase: Phase 1
Development of Stem Cell Lines in Children With Neurofibromatosis Type 1 and Tumors of the Central Nervous System
Development of Stem Cell Lines in Children With Neurofibromatosis Type 1 and Tumors of the Central Nervous System
Enrollment Status: Withdrawn
Publish Date: February 07, 2024
Intervention Type: Diagnostic test
Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG)
Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG)
Enrollment Status: Completed
Publish Date: December 13, 2023
Intervention Type: Drug
Study Drugs: Dabrafenib, Trametinib, Carboplatin with Vincristine
Study Phase: Phase 2
Frameshift Peptides of Children With Neurofibromatosis Type 1 (NF1) and Either Low-Grade Gliomas or Plexiform Neurofibromas
Frameshift Peptides of Children With Neurofibromatosis Type 1 (NF1) and Either Low-Grade Gliomas or Plexiform Neurofibromas
Enrollment Status: Completed
Publish Date: August 31, 2022
Intervention Type: Genetic
A Study of INFUSE Bone Graft (Recombinant Human Bone Morphogenetic Protein-2/Absorbable Collagen Sponge) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis 1 (NF1)
A Study of INFUSE Bone Graft (Recombinant Human Bone Morphogenetic Protein-2/Absorbable Collagen Sponge) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis 1 (NF1)
Enrollment Status: Terminated
Publish Date: October 27, 2021
Intervention Type: Procedure, Device
Study Phase: Not Applicable
Phase I Study of CDK 4-6 Inhibitor PD-0332991 (Palbociclib; IBRANCE) in Children With Recurrent, Progressive or Refractory Central Nervous System Tumors
Phase I Study of CDK 4-6 Inhibitor PD-0332991 (Palbociclib; IBRANCE) in Children With Recurrent, Progressive or Refractory Central Nervous System Tumors
Enrollment Status: Terminated
Publish Date: March 02, 2021
Intervention Type: Other, Drug
Study Phase: Phase 1
Phase II Study of Peginterferon Alfa-2b (Sylatron) for Pediatric Patients With Unresectable or Recurrent Craniopharyngioma
Phase II Study of Peginterferon Alfa-2b (Sylatron) for Pediatric Patients With Unresectable or Recurrent Craniopharyngioma
Enrollment Status: Terminated
Publish Date: February 24, 2020
Intervention Type: Other, Biological
Study Phase: Phase 2
View 13 Less Clinical Trials

260 Total Publications

Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial.
Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial.
Journal: Nature medicine
Published: April 16, 2025
Similar Doctors
Distinguished in Metastatic Brain Tumor
Dr. Mateo Ziu
Neurosurgery | General Surgery | Neurology
Distinguished in Metastatic Brain Tumor
Dr. Mateo Ziu
Neurosurgery | General Surgery | Neurology

Inova Health Care Services

3300 Gallows Rd, 
Falls Church, VA 
 (12.5 miles away)
703-776-4001
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Mateo Ziu is a Neurosurgery specialist and a General Surgeon in Falls Church, Virginia. Dr. Ziu is rated as a Distinguished provider by MediFind in the treatment of Metastatic Brain Tumor. His top areas of expertise are Metastatic Brain Tumor, Glioblastoma, Brain Tumor, Awake Craniotomy, and Laminectomy. Dr. Ziu is currently accepting new patients.

Distinguished in Metastatic Brain Tumor
Dr. Haroon Ahmad
Neurology
Distinguished in Metastatic Brain Tumor
Dr. Haroon Ahmad
Neurology

University Of Maryland Neurology Associates PA

22 S Green St, 
Baltimore, MD 
 (32.6 miles away)
410-328-4323
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Haroon Ahmad is a Neurologist in Baltimore, Maryland. Dr. Ahmad is rated as a Distinguished provider by MediFind in the treatment of Metastatic Brain Tumor. His top areas of expertise are Oligodendroglioma, Astrocytoma, Glioma, and Glioblastoma.

Distinguished in Metastatic Brain Tumor
Dr. David O. Kamson
Neurology
Distinguished in Metastatic Brain Tumor
Dr. David O. Kamson
Neurology

Johns Hopkins University

5755 Cedar Ln, 
Columbia, MD 
 (21.0 miles away)
410-740-7544
Languages Spoken:
English, Hungarian
See accepted insurances
Accepting New Patients
Offers Telehealth

David Kamson is a Neurologist in Columbia, Maryland. Dr. Kamson is rated as a Distinguished provider by MediFind in the treatment of Metastatic Brain Tumor. His top areas of expertise are Brain Tumor, Glioblastoma, Gliosarcoma, Metastatic Brain Tumor, and Hormone Replacement Therapy (HRT). Dr. Kamson is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Packer's expertise for a condition
ConditionClose
View All 7 Elite Conditions
View All 8 Distinguished Conditions
View All 12 Advanced Conditions
View All 20 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile